SCHEMBL3392371

SCHEMBL3392371

CC(=O)Nc1ccc(-c2cc(C(N)=O)c3[nH]nc(C4CCN(S(=O)(=O)c5cn(C)c(C)n5)CC4)c3c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
HSD17B10 Q99714 1/20 0.39
IKBKB O14920 11/20 0.38
CHUK O15111 4/20 0.38
TP53 P04637 1/20 0.38
TLR8 Q9NR97 2/20 0.38
TLR7 Q9NYK1 2/20 0.38
TLR9 Q9NR96 1/20 0.38
AURKA O14965 1/20 0.37
FLT3 P36888 1/20 0.37
CSNK1E P49674 1/20 0.37
BTK Q06187 1/20 0.37
USP30 Q70CQ3 1/20 0.36
SMYD3 Q9H7B4 2/20 0.34
BRD4 O60885 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3395738 0.92 BTK (0.43) HSD17B10IKBKBCHUKTLR8TLR7
SCHEMBL3392925 0.89 IKBKB (0.49) IKBKBCHUKTLR8TLR7TLR9
SCHEMBL3393313 0.88 IKBKB (0.41) IKBKBCHUKTLR8TLR7TLR9
SCHEMBL3392013 0.85 IKBKB (0.41) IKBKBCHUKTLR8TLR7TLR9
SCHEMBL3395813 0.84 TLR9 (0.39) IKBKBCHUKTLR8TLR7TLR9
SCHEMBL3396389 0.83 IKBKB (0.55) MAPTHSD17B10IKBKBCHUKTP53
SCHEMBL3395796 0.78 IKBKB (0.47) IKBKBCHUKBTKUSP30
SCHEMBL3395478 0.78 IKBKB (0.49) IKBKBCHUKAURKAFLT3CSNK1E
SCHEMBL14365477 0.77 USP30 (0.40) MAPTIKBKBCHUKBTKUSP30
SCHEMBL3395713 0.76 PTPN2 (0.48) MAPTHSD17B10USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501780-B2 Indazole carboxamides and their use GLAXOSMITHKLINE LLC (US) 2013-08-06 US disclosed
US-8501780-B2 Indazole carboxamides and their use GLAXOSMITHKLINE LLC (US) 2013-08-06 US disclosed
US-8501780-B2 Indazole carboxamides and their use GLAXOSMITHKLINE LLC (US) 2013-08-06 US disclosed
EP-1758578-B1 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE GLAXOSMITHKLINE LLC (US) 2010-12-29 EP disclosed
EP-1758578-B1 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE GLAXOSMITHKLINE LLC (US) 2010-12-29 EP disclosed
US-20070281933-A1 Novel Indazole Carboxamides And Their Use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-06 US disclosed
US-20070281933-A1 Novel Indazole Carboxamides And Their Use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-06 US disclosed
US-20070281933-A1 Novel Indazole Carboxamides And Their Use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281933-A1 Novel Indazole Carboxamides And Their Use IKBKG, IRAK2, NFKBIA MAPT 3416/4885HSD17B10 3021/4885IKBKB 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.